AstraZeneca PLC (AZN)
| Market Cap | 292.18B +40.9% |
| Revenue (ttm) | 58.13B +13.5% |
| Net Income | 9.40B +44.7% |
| EPS | 6.02 +45.0% |
| Shares Out | 1.55B |
| PE Ratio | 31.46 |
| Forward PE | 38.37 |
| Dividend | $3.13 (1.65%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 2,542,631 |
| Open | 189.06 |
| Previous Close | 184.32 |
| Day's Range | 186.32 - 190.70 |
| 52-Week Range | 122.26 - 195.00 |
| Beta | 0.19 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Feb 10, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
US FDA rejects AstraZeneca's easier-to-use version of lupus therapy
AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an easier-to-use version of lupus therapy Saphnelo, pushing back the timeline for a possible approval to the...
AstraZeneca begins trading on the New York Stock Exchange
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Compa...
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
AstraZeneca has announced it's investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs. The developments come at a critical time for the pharma i...
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions
At least five world leaders have visited Beijing in January alone. The high-level visits come as countries navigate tense U.S. relations.
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...
AstraZeneca sets out $15 billion China investment during Starmer visit
UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Mi...
University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation
Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborations Agreement builds on long-established partnership and demons...
Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip
Starmer brings nearly 60 business and cultural groups on first U.K. leader visit to China in eight years. Talks with Xi and Li focus on trade, investment and national security.
Astrazeneca CEO Soriot to join Starmer delegation to China, source says
UK-headquartered pharmaceutical firm AstraZeneca's AZN.L) CEO Pascal Soriot will join Prime Minister Keir Starmer's trip to China this week, said a source familiar with the matter, as Britain seeks to...
AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach
AstraZeneca Plc (NASDAQ: AZN) said Tuesday it will voluntarily delist its American Depositary Shares and certain guaranteed debt securities from the Nasdaq as it transitions to a direct stock listing ...
AstraZeneca to delist from Nasdaq, join NYSE in February
AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange,...
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AstraZeneca to acquire Modella AI to speed oncology drug research
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale
BOSTON--(BUSINESS WIRE)-- #AstraZeneca--Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale.
AstraZeneca: Oncology Dominance Justifies New All-Time Highs
AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its onc...
AstraZeneca names Rick Suarez head of US biopharmaceuticals unit
AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufac...
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the C...
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, scienc...
These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.
With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung ...